Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma
July 7th 2017
The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.